{"disease":{"id":"hr-metastatic-breast-cancer","name":"hr metastatic breast cancer"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."}],"pipeline":[{"drug_id":"endocrine-therapy-1","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 1","generic_name":"endocrine-therapy-1","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 1","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 1"},{"drug_id":"endocrine-therapy-2","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 2","generic_name":"endocrine-therapy-2","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 2","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 2"},{"drug_id":"pf-06873600","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06873600","generic_name":"pf-06873600","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06873600 tablet for oral dosing","quality_score":null,"revenue":null,"mechanism":"PF-06873600 tablet for oral dosing"}],"offLabel":[],"totalMarketed":5,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT07476170","title":"Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China","phase":"","overall_status":"RECRUITING","enrollment_count":14000,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06998108","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"BeBetter Med Inc","has_results":false},{"nct_id":"NCT05904964","title":"Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07393321","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Nanjing Chia-tai Tianqing Pharmaceutical","has_results":false},{"nct_id":"NCT03921866","title":"UK Ibrance Patient Program (IPP) Study","phase":"","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04819243","title":"PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":178,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05853432","title":"A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03519178","title":"A Study of PF-06873600 in People With Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06774027","title":"Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT05044988","title":"A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04197999","title":"A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"GlycoMimetics Incorporated","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03706573","title":"Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}